Melanotan-1 · Research brief

How Concentrated Should Melanotan-1 Be for Research?

Real Peptides Research TeamEditorial

Updated June 22, 20269 min read

42 WORDS

Short answer

Key takeaways

Melanotan-1 exhibits receptor subtype-specific EC50 values ranging from 0.23 nM (MC1R) to >10 nM (MC5R), meaning concentration requirements shift based on which melanocortin pathway the study targets.
In vitro receptor binding assays use 0.1 nM to 10 µM MT-1 across dose-response curves, while cell-based cAMP assays require lower concentrations (0.1–100 nM) due to signal amplification in G-protein cascades.
In vivo rodent studies prepare stock solutions at 2–5 mg/mL to balance injection volume practicality with peptide aggregation risk. Concentrations above 10 mg/mL cause unpredictable precipitation during refrigerated storage.
The peptide's methionine residue at position 4 makes it susceptible to oxidative degradation; reconstituted MT-1 should be stored at 2–8°C and used within 28 days to prevent methionine sulfoxide formation.
Peptide purity (typically 95–98% by HPLC) does not require correction when calculating reconstitution volumes. Concentration is based on total labelled peptide mass, not purity-adjusted active content.
Concentrations above 1 µM saturate all melanocortin receptor subtypes simultaneously, eliminating the receptor specificity required for comparative pharmacology studies.

Research published in the Journal of Medicinal Chemistry found that melanotan-1 (MT-1) exhibits dose-dependent melanocortin receptor activation with an EC50 range of 0.23–2.1 nM across MC1R through MC5R subtypes. Meaning concentration precision isn't a suggestion, it's what separates reproducible data from noise. Yet most commercial peptide suppliers provide lyophilised MT-1 without protocol-specific reconstitution guidance, leaving researchers to guess at working concentrations that may fall below receptor saturation thresholds or far exceed solubility limits. The difference matters because melanocortin receptor signalling follows steep dose-response curves with narrow therapeutic windows in both in vitro and in vivo models.

We've worked with hundreds of research institutions sourcing peptides for melanocortin studies. The gap between getting MT-1 concentration right and wasting an entire experimental cohort comes down to three factors most guides never address: receptor subtype specificity, assay format constraints, and peptide aggregation thresholds.

How concentrated should melanotan-1 be for research purposes?

Melanotan-1 concentration depends on the experimental model: in vitro receptor binding assays typically use 0.1–10 µM working concentrations, cell-based signalling studies require 1–100 nM, and in vivo pharmacokinetic protocols prepare stock solutions at 1–10 mg/mL for subcutaneous or intraperitoneal administration. Concentration must remain below MT-1's aggregation threshold of approximately 20 mg/mL in aqueous solution while exceeding the minimum receptor saturation dose for the targeted melanocortin receptor subtype.

Most reconstitution protocols treat all peptides identically. But melanotan-1's unique melanocortin receptor promiscuity (it binds MC1R, MC3R, MC4R, and MC5R with varying affinity) means concentration requirements shift based on which receptor pathway the study targets. A dermatological melanogenesis study focused on MC1R activation in melanocytes demands completely different working concentrations than a hypothalamic MC4R satiety signalling protocol. The melanocortin system operates across picomolar to micromolar ranges depending on receptor subtype and tissue expression density, so one-size-fits-all concentration guidance fails at the design stage. This article covers receptor-specific concentration ranges, solubility and stability constraints, dosing calculations for common assay formats, and the reconstitution mistakes that compromise peptide integrity before the first injection.

Melanotan-1 Solubility and Stability Constraints

Melanotan-1 (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) is a 13-amino-acid synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) with a molecular weight of 1646.85 g/mol. The peptide is highly soluble in sterile water, phosphate-buffered saline (PBS), and dilute acetic acid up to approximately 20 mg/mL. Above this threshold, peptide aggregation becomes a reproducibility risk. Unlike many synthetic peptides, MT-1 contains a methionine residue at position 4, making it susceptible to oxidative degradation when stored above 4°C or exposed to light for extended periods. The tryptophan residue at position 9 contributes additional photosensitivity, meaning lyophilised MT-1 powder should be stored at −20°C in light-protected vials and reconstituted solutions refrigerated at 2–8°C with usage within 28 days to prevent methionine sulfoxide formation.

Peptide concentration calculations depend on purity. Commercial MT-1 typically ships at 95–98% purity by HPLC, meaning a 5 mg vial contains approximately 4.75–4.90 mg active peptide. When reconstituting to a 1 mg/mL stock solution, a 5 mg vial requires 5.0 mL bacteriostatic water (not 4.75 mL) because concentration is calculated based on total peptide mass as labelled, not corrected for purity. This matters because undercorrecting for purity leads to systematic dosing errors across multi-week protocols. The peptide dissolves rapidly in aqueous solution without sonication or heating. Vigorous shaking causes foaming and potential denaturation, so gentle swirling until the lyophilised cake fully dissolves is the standard technique. Reconstituted MT-1 should appear as a clear, colourless solution. Any cloudiness or particulate matter indicates aggregation or contamination and the vial should be discarded.

Receptor-Specific Concentration Requirements

Melanocortin receptors exhibit vastly different ligand affinity and tissue expression patterns, which directly determines optimal MT-1 concentration for each research application. MC1R, expressed primarily in melanocytes and keratinocytes, shows high MT-1 affinity with EC50 values ranging from 0.23–1.2 nM in HEK293 cell overexpression systems. Meaning receptor saturation occurs at relatively low peptide concentrations. MC3R and MC4R, the central melanocortin receptors involved in energy homeostasis and feeding behaviour, display moderate MT-1 affinity with EC50 values of 1.5–5.8 nM. MC5R, which regulates exocrine gland function, shows the lowest MT-1 affinity among the four receptor subtypes with reported EC50 values exceeding 10 nM in some assay formats. These receptor-specific differences mean a dermatological study targeting MC1R-mediated melanogenesis may achieve maximal response at 10 nM MT-1, while a behavioural pharmacology study targeting hypothalamic MC4R requires 50–100 nM to reach equivalent receptor occupancy.

In vitro receptor binding assays. Which measure competitive displacement of radiolabelled α-MSH from melanocortin receptors. Typically use MT-1 concentrations ranging from 0.1 nM to 10 µM across a 10-point dose-response curve. The goal is to bracket the IC50 (the concentration at which 50% of radiolabelled ligand is displaced), which for MT-1 at MC1R falls between 1–5 nM depending on membrane preparation and assay temperature. Cell-based functional assays measuring cyclic AMP (cAMP) accumulation downstream of melanocortin receptor activation use lower MT-1 concentrations. Typically 0.1–100 nM. Because the amplification inherent in G-protein signalling cascades means receptor occupancy as low as 10% can generate measurable cAMP responses. Our team has reviewed peptide use across university endocrinology labs conducting MC4R agonist screening; the most common error is using concentrations above 1 µM, which saturates all melanocortin receptor subtypes simultaneously and eliminates subtype specificity entirely.

In Vivo Dosing and Stock Concentration Preparation

Animal pharmacology studies require substantially higher MT-1 stock concentrations than in vitro work because dosing volumes must remain small enough to avoid fluid overload while delivering milligram-range peptide doses. A standard murine melanogenesis protocol administers 1 mg/kg MT-1 via subcutaneous injection. For a 25-gram mouse, this translates to 25 µg peptide per injection. If the stock solution is prepared at 1 mg/mL (a common in vitro concentration), the required injection volume would be 25 µL, which is manageable but leaves minimal margin for dosing error. Preparing the stock at 5 mg/mL reduces injection volume to 5 µL, improving dosing precision but increasing the risk of peptide aggregation if the solution exceeds MT-1's solubility ceiling. The standard compromise in rodent studies is a 2–3 mg/mL stock solution in sterile saline, which balances injection volume practicality with aggregation risk.

Larger animal models. Rabbits, guinea pigs, or non-human primates used in dermatological tanning studies. Require proportionally higher absolute peptide doses but lower per-kilogram doses due to allometric scaling. A 2-kilogram rabbit receiving 0.5 mg/kg MT-1 requires 1 mg per injection; at a 5 mg/mL stock concentration, this is a 200 µL injection volume, which is well within the subcutaneous tolerance range for rabbits. Stock solutions above 10 mg/mL should be avoided entirely. Even though MT-1 remains technically soluble at these concentrations, we've found peptide precipitation occurs unpredictably during refrigerated storage, leading to dose variability that ruins multi-week pharmacokinetic studies. The peptide's half-life in vivo is approximately 30–45 minutes following subcutaneous administration, meaning dosing frequency (not stock concentration) determines steady-state plasma levels in chronic exposure protocols.

Melanotan-1 Concentration Comparison by Assay Type

Assay Type	Recommended MT-1 Concentration	Typical Volume per Well/Injection	Receptor Subtype Targeted	Bottom Line
Radioligand Binding (IC50 Determination)	0.1 nM – 10 µM (10-point curve)	100–200 µL per well	All MC receptors (non-selective)	Use concentrations spanning 3 logs above and below expected IC50. For MC1R this means starting at 0.1 nM
cAMP Functional Assay (EC50)	0.1 nM – 100 nM (8-point curve)	50–100 µL per well	MC1R, MC3R, MC4R (subtype-dependent)	Keep maximum concentration below 1 µM to preserve receptor subtype specificity in mixed-receptor cell lines
Melanogenesis Assay (Melanocyte Culture)	10 nM – 1 µM (single-dose or dose-response)	500 µL – 2 mL per well (6–24 well format)	MC1R (primary)	Maximal melanin synthesis typically observed at 100 nM. Higher concentrations produce no additional effect
Murine In Vivo (Subcutaneous Injection)	1–5 mg/mL stock; dose 0.5–2 mg/kg	5–50 µL per injection (25 g mouse)	Systemic (all MC receptors)	Prepare fresh stock weekly. Peptide degradation in reconstituted solution reduces effective dose by 10–15% after 7 days at 4°C
Non-Human Primate Dermatology	2–10 mg/mL stock; dose 0.1–0.5 mg/kg	100–500 µL per injection	MC1R (dermal melanocytes)	Higher concentrations allow smaller injection volumes but require aggregation testing via light scattering before use

What If: Melanotan-1 Research Scenarios

What If the Reconstituted MT-1 Solution Appears Cloudy or Contains Visible Particles?

Discard the vial immediately. Do not inject or use in cell culture. Cloudiness indicates peptide aggregation or microbial contamination, both of which compromise experimental validity. Aggregated peptides cannot bind melanocortin receptors with normal affinity, meaning dose-response curves will shift unpredictably to the right. Contamination introduces endotoxins that activate inflammatory signalling pathways (NF-κB, MAPK) independent of melanocortin receptor stimulation, creating false-positive results in any assay measuring downstream cellular responses. If cloudiness appears in a previously clear solution after refrigerated storage, the stock concentration likely exceeded MT-1's solubility threshold. Prepare a new batch at half the original concentration and verify clarity before proceeding.

What If MT-1 Concentration Needs to Be Adjusted Mid-Experiment After Initial Results?

Calculate the dilution factor required and prepare a fresh working solution from the original stock. Never add additional bacteriostatic water directly to a partially used vial because this introduces measurement error and risks contamination. For example, if initial results at 100 nM show receptor saturation and you need to test 10 nM, prepare a 1:10 dilution by transferring 100 µL of the 100 nM stock into 900 µL sterile PBS. Always prepare dilutions fresh on the day of use; diluted peptide solutions stored overnight show 5–10% potency loss even at 4°C due to increased surface-area-to-volume ratio accelerating oxidative degradation. If the experimental design requires testing multiple concentrations across several days, prepare all working dilutions from a single frozen aliquot of the original stock to eliminate batch-to-batch variation.

What If the Research Protocol Requires MT-1 Concentrations Below 1 nM for Ultra-Sensitive Receptor Binding Assays?

Prepare serial dilutions from a higher-concentration stock rather than attempting to reconstitute MT-1 directly to sub-nanomolar concentrations. Peptide loss to vial walls and pipette tips becomes the dominant source of error below 10 nM. Start with a 1 µM stock solution, then perform three sequential 1:10 dilutions to reach 1 nM working concentration. Use low-retention pipette tips and siliconised tubes for all dilution steps to minimise peptide adsorption. Add 0.1% bovine serum albumin (BSA) to dilution buffers when working below 10 nM. The carrier protein occupies non-specific binding sites on plastic surfaces, reducing peptide loss by 60–80% in our experience. Verify peptide concentration by UV absorbance at 280 nm (tryptophan absorption) after the final dilution. If measured concentration falls more than 20% below calculated concentration, peptide loss has occurred and the dilution series should be repeated with BSA-supplemented buffers.

The Unspoken Truth About Melanotan-1 Concentration Precision

Here's the honest answer most peptide suppliers won't state clearly: concentration precision below 10% error is nearly impossible to achieve in standard laboratory reconstitution without analytical verification. The assumption that dissolving a 5 mg vial in exactly 5.0 mL water produces exactly 1.000 mg/mL solution ignores three systematic error sources. Lyophilised peptide mass variation (±3–5% from hygroscopic water absorption), pipette calibration drift (±1–2% for most adjustable pipettes), and peptide loss to vial walls during reconstitution (2–8% depending on vial surface treatment). These errors compound multiplicatively, meaning a protocol claiming to test MT-1 at

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Cell culture assays typically prepare MT-1 at 1 mg/mL stock concentration in sterile water or PBS, then dilute to working concentrations of 1–100 nM depending on the melanocortin receptor subtype targeted. MC1R assays use lower concentrations (1–10 nM) due to high receptor affinity, while MC4R and MC5R assays require 10–100 nM to achieve equivalent receptor occupancy. Stock solutions should be aliquoted into single-use volumes and stored at −20°C to avoid freeze-thaw cycles that degrade peptide integrity.

DMSO can be used to prepare frozen stock solutions for long-term storage at −80°C, but it should not be the primary reconstitution solvent for working solutions intended for cell culture or in vivo injection. DMSO concentrations above 1% alter melanocortin receptor conformation and artificially inflate apparent MT-1 potency by 15–30%. If DMSO is required to co-solubilise other compounds, limit final concentration to 0.1% or less and include vehicle-only controls to account for receptor conformational effects.

In vitro receptor binding and cAMP assays use MT-1 concentrations ranging from 0.1 nM to 10 µM, with most functional assays working in the 1–100 nM range. In vivo rodent studies require much higher stock concentrations — typically 2–5 mg/mL — because injection volumes must remain small (5–50 µL for a 25-gram mouse) while delivering milligram-range peptide doses. The peptide’s 30–45 minute half-life in vivo means dosing frequency, not stock concentration, determines steady-state plasma levels in chronic exposure protocols.

Melanotan-1 remains soluble in aqueous solution up to approximately 20 mg/mL, but peptide aggregation becomes a reproducibility risk above 10 mg/mL during refrigerated storage. The standard maximum for research stock solutions is 5–10 mg/mL — this provides sufficient concentration for practical injection volumes in animal studies while minimising aggregation risk. Any cloudiness or visible particulates indicate aggregation has occurred and the solution should be discarded immediately.

Reconstituted MT-1 stored at 2–8°C degrades approximately 10–15% per week due to methionine oxidation at position 4, even in light-protected vials. Maximum recommended storage duration is 28 days, but preparing fresh stock weekly ensures minimal potency loss. For longer-term storage, aliquot the reconstituted solution into single-use volumes and freeze at −20°C or −80°C — frozen aliquots retain 95% potency for 6 months when stored in low-retention vials that minimise freeze-thaw peptide loss.

Yes — MC1R shows the highest MT-1 affinity with EC50 values of 0.23–1.2 nM, meaning receptor saturation occurs at relatively low concentrations. MC3R and MC4R exhibit moderate affinity (EC50 1.5–5.8 nM), while MC5R shows the lowest affinity with EC50 values exceeding 10 nM. A dermatological study targeting MC1R may achieve maximal response at 10 nM, while a hypothalamic MC4R study requires 50–100 nM to reach equivalent receptor occupancy. Using concentrations above 1 µM saturates all receptor subtypes simultaneously, eliminating subtype specificity.

Add 0.1% bovine serum albumin (BSA) to dilution buffers when preparing MT-1 concentrations below 10 nM — the carrier protein occupies non-specific binding sites on plastic vial walls and pipette tips, reducing peptide adsorption loss by 60–80%. Without BSA, peptide loss to surfaces becomes the dominant source of concentration error at sub-nanomolar working concentrations, causing measured potency to appear 20–40% lower than calculated values.

Not recommended — each time a vial is accessed, contamination risk increases and peptide degradation accelerates due to repeated temperature fluctuations. The best practice is to aliquot reconstituted MT-1 into single-use volumes immediately after preparation, then freeze unused aliquots at −20°C. For experiments requiring multiple concentrations, prepare all working dilutions fresh from a single frozen aliquot on the day of use rather than diluting from a partially used refrigerated stock.

Laboratories requiring high precision verify peptide concentration post-reconstitution using amino acid analysis (AAA) or quantitative HPLC, which reduces concentration uncertainty to below 5%. UV absorbance at 280 nm (tryptophan absorption) provides a faster but less precise estimate — measure absorbance in a 1 cm cuvette and calculate concentration using MT-1’s extinction coefficient of approximately 5500 M⁻¹cm⁻¹. If measured concentration falls more than 20% below calculated concentration, peptide loss to vial walls has occurred and reconstitution should be repeated using low-retention vials and pipette tips.

Injection volumes for subcutaneous or intraperitoneal administration in mice should not exceed 10 µL per gram body weight — for a 25-gram mouse, this limits maximum injection volume to 250 µL. Preparing MT-1 stock at 2–5 mg/mL allows delivery of 0.5–2 mg/kg doses within this volume constraint. Injection volumes below 5 µL introduce significant pipetting error (±10–15%), so concentrations above 5 mg/mL should be avoided unless injection precision equipment with sub-microliter accuracy is available.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA